Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 May;112(1):137–142. doi: 10.1111/j.1476-5381.1994.tb13043.x

Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium.

M Böhm 1, C Weinhold 1, R H Schwinger 1, J Müller-Ehmsen 1, D Böhm 1, H Reichenspurner 1, B Reichart 1, E Erdmann 1
PMCID: PMC1910273  PMID: 8032635

Abstract

1. The aim of the present study was to determine the effect of the nucleoside transporter inhibitor, draflazine, on the force of contraction in human myocardium and the affinity of the compound for the nucleoside transporter. Nucleoside transport inhibitors, like draflazine, are of potential importance for cardiopreservation of donor hearts for heart transplantation. 2. Functional experiments were performed in isolated electrically driven (1 Hz, 1.8 mmol l-1 Ca2+) human atrial trabeculae and ventricular papillary muscle strips. The affinity of draflazine for the myocardial nucleoside transporter was studied in isolated membranes from human ventricular myocardium and human erythrocytes in radioligand binding experiments using [3H]-nitrobenzylthioinosine ([3H]-NBTI). Dipyridamole was studied for comparison. 3. In membranes from human myocardium and erythrocytes, [3H]-NTBI labelled 1.18 pmol mg-1 protein and 23.0 pmol mg-1 protein, respectively, nucleoside transporter molecules with a KD value of 0.8 nmol l-1. Draflazine concentration-dependently inhibited binding of [3H]-NBTI to myocardial and erythrocyte membranes with a K(i)-value of 4.5 nmol l-1. The potency as judged from the K(i) values was ten times greater than that of dipyridamole in both myocardial and erythrocyte membranes. 4. Draflazine, at concentrations up to 100 mumol l-1, did not produce negative inotropic effects in atrial and ventricular myocardium. (-)-N6-phenylisopropyladenosine (R-PIA) and carbachol did not reduce force of contraction in ventricular myocardium, but exerted concentration-dependent direct negative inotropic effects in atrial myocardium. 5. The data provide evidence that draflazine specifically binds to the nucleoside transporter of the human heart and erythrocytes with high affinity.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
137

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahn H. S., Crim W., Romano M., Sybertz E., Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol. 1989 Oct 1;38(19):3331–3339. doi: 10.1016/0006-2952(89)90631-x. [DOI] [PubMed] [Google Scholar]
  2. Belardinelli L., Linden J., Berne R. M. The cardiac effects of adenosine. Prog Cardiovasc Dis. 1989 Jul-Aug;32(1):73–97. doi: 10.1016/0033-0620(89)90015-7. [DOI] [PubMed] [Google Scholar]
  3. Berne R. M. The role of adenosine in the regulation of coronary blood flow. Circ Res. 1980 Dec;47(6):807–813. doi: 10.1161/01.res.47.6.807. [DOI] [PubMed] [Google Scholar]
  4. Blass K. E., Block H. U., Förster W., Pönicke K. Dipyridamole: a potent stimulator of prostacyclin (PGI2) biosynthesis. Br J Pharmacol. 1980 Jan;68(1):71–73. doi: 10.1111/j.1476-5381.1980.tb10700.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bunch F. T., Thornton J., Cohen M. V., Downey J. M. Adenosine is an endogenous protectant against stunning during repetitive ischemic episodes in the heart. Am Heart J. 1992 Dec;124(6):1440–1446. doi: 10.1016/0002-8703(92)90055-z. [DOI] [PubMed] [Google Scholar]
  6. Böhm M., Brückner R., Hackbarth I., Haubitz B., Linhart R., Meyer W., Schmidt B., Schmitz W., Scholz H. Adenosine inhibition of catecholamine-induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations. Evidence against a cyclic AMP- and cyclic GMP-dependent effect. J Pharmacol Exp Ther. 1984 Aug;230(2):483–492. [PubMed] [Google Scholar]
  7. Böhm M., Brückner R., Schäfer H., Schmitz W., Scholz H. Inhibition of the effects of adenosine on force of contraction and the slow calcium inward current by pertussis toxin is associated with myocardial lesions. Cardiovasc Res. 1988 Feb;22(2):87–94. doi: 10.1093/cvr/22.2.87. [DOI] [PubMed] [Google Scholar]
  8. Böhm M., Diet F., Pieske B., Erdmann E. Screening of positive inotropic agents in isolated cardiac preparations from different sources. J Pharmacol Methods. 1989 Mar;21(1):33–44. doi: 10.1016/0160-5402(89)90020-x. [DOI] [PubMed] [Google Scholar]
  9. Böhm M., Meyer W., Mügge A., Schmitz W., Scholz H. Functional evidence for the existence of adenosine receptors in the human heart. Eur J Pharmacol. 1985 Oct 22;116(3):323–326. doi: 10.1016/0014-2999(85)90170-0. [DOI] [PubMed] [Google Scholar]
  10. Böhm M., Pieske B., Ungerer M., Erdmann E. Characterization of A1 adenosine receptors in atrial and ventricular myocardium from diseased human hearts. Circ Res. 1989 Nov;65(5):1201–1211. doi: 10.1161/01.res.65.5.1201. [DOI] [PubMed] [Google Scholar]
  11. Chang-Chun C., Masuda M., Szabò Z., Szerafin T., Szècsi J., Van Belle H., Flameng W. Nucleoside transport inhibition mediates lidoflazine-induced cardioprotection during intermittent aortic crossclamping. J Thorac Cardiovasc Surg. 1992 Dec;104(6):1602–1609. [PubMed] [Google Scholar]
  12. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  13. Cronstein B. N., Kramer S. B., Rosenstein E. D., Weissmann G., Hirschhorn R. Adenosine modulates the generation of superoxide anion by stimulated human neutrophils via interaction with a specific cell surface receptor. Ann N Y Acad Sci. 1985;451:291–301. doi: 10.1111/j.1749-6632.1985.tb27120.x. [DOI] [PubMed] [Google Scholar]
  14. DiMarco J. P., Sellers T. D., Berne R. M., West G. A., Belardinelli L. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation. 1983 Dec;68(6):1254–1263. doi: 10.1161/01.cir.68.6.1254. [DOI] [PubMed] [Google Scholar]
  15. Dobson J. G., Jr, Ordway R. W., Fenton R. A. Endogenous adenosine inhibits catecholamine contractile responses in normoxic hearts. Am J Physiol. 1986 Aug;251(2 Pt 2):H455–H462. doi: 10.1152/ajpheart.1986.251.2.H455. [DOI] [PubMed] [Google Scholar]
  16. Flameng W., Sukehiro S., Möllhoff T., Van Belle H., Janssen P. A new concept of long-term donor heart preservation: nucleoside transport inhibition. J Heart Lung Transplant. 1991 Nov-Dec;10(6):990–998. [PubMed] [Google Scholar]
  17. Foley D. H., Herlihy J. T., Thompson C. I., Rubio R., Berne R. M. Increased adenosine formation by rat myocardium with acute aortic constriction. J Mol Cell Cardiol. 1978 Mar;10(3):293–300. doi: 10.1016/0022-2828(78)90352-8. [DOI] [PubMed] [Google Scholar]
  18. Forman M. B., Velasco C. E., Jackson E. K. Adenosine attenuates reperfusion injury following regional myocardial ischaemia. Cardiovasc Res. 1993 Jan;27(1):9–17. doi: 10.1093/cvr/27.1.9. [DOI] [PubMed] [Google Scholar]
  19. Fox A. C., Reed G. E., Glassman E., Kaltman A. J., Silk B. B. Release of adenosine from human hearts during angina induced by rapid atrial pacing. J Clin Invest. 1974 May;53(5):1447–1457. doi: 10.1172/JCI107693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Heck C. F., Shumway S. J., Kaye M. P. The Registry of the International Society for Heart Transplantation: sixth official report--1989. J Heart Transplant. 1989 Jul-Aug;8(4):271–276. [PubMed] [Google Scholar]
  21. Klabunde R. E., Althouse D. G. Adenosine metabolism in dog whole blood: effects of dipyridamole. Life Sci. 1981 Jun 8;28(23):2631–2641. doi: 10.1016/0024-3205(81)90721-9. [DOI] [PubMed] [Google Scholar]
  22. Klabunde R. E. Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol. 1983 Sep 16;93(1-2):21–26. doi: 10.1016/0014-2999(83)90026-2. [DOI] [PubMed] [Google Scholar]
  23. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  24. Lasley R. D., Rhee J. W., Van Wylen D. G., Mentzer R. M., Jr Adenosine A1 receptor mediated protection of the globally ischemic isolated rat heart. J Mol Cell Cardiol. 1990 Jan;22(1):39–47. doi: 10.1016/0022-2828(90)90970-d. [DOI] [PubMed] [Google Scholar]
  25. Masuda M., Chang-Chun C., Möllhoff T., Van Belle H., Flameng W. Effects of nucleoside transport inhibition on long-term ex vivo preservation of canine hearts. J Thorac Cardiovasc Surg. 1992 Dec;104(6):1610–1617. [PubMed] [Google Scholar]
  26. McKenzie J. E., McCoy F. P., Bockman E. L. Myocardial adenosine and coronary resistance during increased cardiac performance. Am J Physiol. 1980 Oct;239(4):H509–H515. doi: 10.1152/ajpheart.1980.239.4.H509. [DOI] [PubMed] [Google Scholar]
  27. Plagemann P. G., Wohlhueter R. M., Woffendin C. Nucleoside and nucleobase transport in animal cells. Biochim Biophys Acta. 1988 Oct 11;947(3):405–443. doi: 10.1016/0304-4157(88)90002-0. [DOI] [PubMed] [Google Scholar]
  28. Schrader J., Baumann G., Gerlach E. Adenosine as inhibitor of myocardial effects of catecholamines. Pflugers Arch. 1977 Nov 25;372(1):29–35. doi: 10.1007/BF00582203. [DOI] [PubMed] [Google Scholar]
  29. Schubert T., Vetter H., Owen P., Reichart B., Opie L. H. Adenosine cardioplegia. Adenosine versus potassium cardioplegia: effects on cardiac arrest and postischemic recovery in the isolated rat heart. J Thorac Cardiovasc Surg. 1989 Dec;98(6):1057–1065. [PubMed] [Google Scholar]
  30. Sollevi A., Lagerkranser M., Irestedt L., Gordon E., Lindquist C. Controlled hypotension with adenosine in cerebral aneurysm surgery. Anesthesiology. 1984 Oct;61(4):400–405. doi: 10.1097/00000542-198410000-00007. [DOI] [PubMed] [Google Scholar]
  31. Van Belle H. Nucleoside transport inhibition: a therapeutic approach to cardioprotection via adenosine? Cardiovasc Res. 1993 Jan;27(1):68–76. doi: 10.1093/cvr/27.1.68. [DOI] [PubMed] [Google Scholar]
  32. Van Belle H., Verheyen W., Ver Donck K., Janssen P. A., Robertson J. I. Prevention of catecholamine-induced cardiac damage and death with a nucleoside transport inhibitor. J Cardiovasc Pharmacol. 1992 Aug;20(2):173–178. doi: 10.1097/00005344-199208000-00001. [DOI] [PubMed] [Google Scholar]
  33. Wainwright C. L., Parratt J. R., Van Belle H. The antiarrhythmic effects of the nucleoside transporter inhibitor, R75231, in anaesthetized pigs. Br J Pharmacol. 1993 Jun;109(2):592–599. doi: 10.1111/j.1476-5381.1993.tb13612.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES